Perigon Wealth Management LLC Has $939,000 Stake in Danaher Corporation (NYSE:DHR)

Perigon Wealth Management LLC decreased its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 65.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,582 shares of the conglomerate's stock after selling 8,587 shares during the period. Perigon Wealth Management LLC's holdings in Danaher were worth $939,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of DHR. Fortis Capital Advisors LLC increased its holdings in shares of Danaher by 1.3% in the fourth quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock valued at $914,000 after purchasing an additional 50 shares in the last quarter. Fayez Sarofim & Co increased its holdings in shares of Danaher by 0.6% in the fourth quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock valued at $1,902,000 after purchasing an additional 50 shares in the last quarter. Coastal Bridge Advisors LLC increased its holdings in shares of Danaher by 4.8% in the fourth quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock valued at $252,000 after purchasing an additional 50 shares in the last quarter. Perennial Investment Advisors LLC increased its holdings in shares of Danaher by 2.2% in the fourth quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate's stock valued at $538,000 after purchasing an additional 51 shares in the last quarter. Finally, Sound View Wealth Advisors Group LLC increased its holdings in shares of Danaher by 3.1% in the fourth quarter. Sound View Wealth Advisors Group LLC now owns 1,739 shares of the conglomerate's stock valued at $399,000 after purchasing an additional 52 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Insider Activity

In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the sale, the chairman now directly owns 3,105,808 shares in the company, valued at $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the sale, the executive vice president now owns 15,179 shares of the company's stock, valued at approximately $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is owned by company insiders.

Danaher Stock Performance

Shares of DHR stock opened at $198.20 on Friday. The firm has a 50-day moving average of $194.84 and a 200-day moving average of $208.33. The company has a market cap of $141.84 billion, a P/E ratio of 38.48, a P/E/G ratio of 2.79 and a beta of 0.77. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.43 and a quick ratio of 1.05. Danaher Corporation has a one year low of $171.00 and a one year high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.58 billion. Danaher had a net margin of 15.81% and a return on equity of 10.80%. Equities research analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.65%. Danaher's dividend payout ratio (DPR) is currently 24.85%.

Analysts Set New Price Targets

DHR has been the subject of a number of research reports. Jefferies Financial Group lowered their price target on shares of Danaher from $260.00 to $230.00 and set a "buy" rating for the company in a report on Tuesday, April 22nd. Argus reduced their price objective on shares of Danaher from $260.00 to $240.00 in a research note on Wednesday, April 23rd. Barclays reaffirmed an "overweight" rating and issued a $225.00 price objective (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. UBS Group reduced their price objective on shares of Danaher from $275.00 to $240.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. Finally, Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, Danaher has a consensus rating of "Moderate Buy" and a consensus target price of $248.61.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.